Literature DB >> 2264005

Voluntary human immunodeficiency virus testing, recidivism, partner notification, and sero-prevalence in a sexually transmitted disease clinic: a need for mandatory testing.

J H Lee1, L Branan, G L Hoff, M L Datwyler, W L Bayer.   

Abstract

Universal, voluntary testing for antibodies to the human immunodeficiency virus (HIV) was offered to 17,092 eligible clients attending a public sexually transmitted disease clinic between March, 1988 and June, 1989. In an environment of legally mandated reporting and partner notification, 15,649 (91.6%) clients were tested, 160 of whom were HIV sero-positive. Client acceptance of testing is discussed, and the serologic data compared with results of a federally funded sero-prevalence survey conducted in-clinic. A recidivism rate of 20% was observed among sero-positive individuals. Of 159 contacts for whom HIV sero-status was determined, 66 (42%) were seropositive. It is proposed that, in the setting of sexually transmitted disease clinics, HIV testing be changed from a voluntary service to a mandatory test. Some benefits of this change are defined.

Entities:  

Keywords:  Empirical Approach; Health Care and Public Health; Kansas City (Missouri) Health Department

Mesh:

Year:  1990        PMID: 2264005     DOI: 10.1097/00007435-199010000-00004

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  3 in total

1.  The outreach-assisted model of partner notification with IDUs.

Authors:  J A Levy; S E Fox
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

2.  Sentinel hospital surveillance of HIV infection in Quebec. Quebec Sentinel Hospital HIV-Seroprevalence Study Group.

Authors:  M Alary; J R Joly; R Parent; M Fauvel; M Dionne
Journal:  CMAJ       Date:  1994-10-01       Impact factor: 8.262

Review 3.  Improving HIV test uptake and case finding with assisted partner notification services.

Authors:  Shona Dalal; Cheryl Johnson; Virginia Fonner; Caitlin E Kennedy; Nandi Siegfried; Carmen Figueroa; Rachel Baggaley
Journal:  AIDS       Date:  2017-08-24       Impact factor: 4.177

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.